Receive The Newest Study Notifications

Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Email Print Friendly Share December 10, 2019 16:10 ET | Source: Iterum Therapeutics plc DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral...

Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”),...

Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

BEVERLY, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that Alfasigma S.p.A (“Alfasigma”), the licensee of Brilacidin for the treatment...

ORYZON Presents New Efficacy Data From its Phase II Trial ALICE Investigating iadademstat in AML

by Lance Smith | Dec 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

MADRID, Spain and CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) — ORYZON Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need,...

Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

by Lance Smith | Dec 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, is providing an update on the...

ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

by Lance Smith | Dec 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT (p < 0.001) 56.7% responder rate for 100 mg without ABT (p < 0.001) Both doses achieved important clinically relevant secondary endpoints including...